All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
Status | Trial ID | Title | Completion date | Category |
---|---|---|---|---|
Ongoing | 2007-002371-13 | A Pilot Phase II combination study of Taxotere (Docetaxel) and Erbitux (Cetuximab) as a NEOadjuvant therapy in patients with “triple-negative” (HR and Her2 negative) operable breast cancer. TENEO Stud... | not-yet-due | |
Not reported Terminated | 2008-003930-19 | Essai multicentrique randomisé de phase II comparant le Taxotère® en monothérapie à l’association Taxotère® plus curcumine en première ou deuxième ligne de traitement des cancers du sein inopérables, ... | 2017-10-30 | due-trials |
Completed, but no date | 2009-011423-31 | Essai pilote de phase II évaluant l'association Taxotère® plus curcumine en première ligne de traitement des cancers de la prostate métastatiques hormono-résistants | bad-data | |
Ongoing | 2009-012853-39 | Phase II trial assessing neoadjuvant therapy with FEC 100 followed by Taxotere® (docetaxel) plus Vectibix® (panitumumab) in patients with operable, HR and Her-2 negative breast cancer. TVA study. | not-yet-due | |
Ongoing | 2012-004103-12 | ISOTOVE study Isotopic study of the intraperitoneal distribution of locoregional post surgery chemotherapy for peritoneal carcinomatosis of ovarian origin Etude ISOTOVE Etude isotopique de la dist... | not-yet-due | |
Ongoing | 2012-005213-39 | Phase II pilot study assessing efficacy of a Cisplatine – Métronomic Cyclophosphamide treatment in Patients with Stade IV Triple Negative breast Cancer Secondary Resistant to Anthracyclines and Taxane... | not-yet-due | |
Not reported | 2013-001275-21 | Phase II study: individualization of dosage of irinotecan in the FOLFIRI according to the genetic polymorphism of UGT1A1 in the first line treatment of metastatic colorectal cancer Etude de phase I... | 2019-12-09 | due-trials |
Completed, but no date, and reported results Terminated | 2013-002138-20 | Multicenter randomized phase II study, double-blind, comparing Taxotere plus curcumin versus Taxotere plus placebo combination in first-line treatment of prostate cancer metastatic castration resistan... | bad-data | |
Exempt | 2020-004552-15 | Phase I/II study of AGuIX nanoparticles with radiotherapy plus concomitant Temozolomide in the treatment of newly diagnosed glioblastoma Etude de phase I/II testant l’association de nanoparticules ... | not-yet-due |